Intel (INTC): Weak Enterprise Crimps DCG Growth - Needham
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Needham & Company analyst, Quinn Bolton, cut his Intel (NASDAQ: INTC) price target to $42 from $43 after the company reported 3Q16 results near the high end of revised guidance and above his forecast.
Guidance for 4Q16 exceeded the analysts forecast but fell short of Street expectations due to anticipated PC supply chain inventory reductions and continued headwinds in the enterprise segment of DCG. Reflecting these continued headwinds, management now expects DCG revenue to increase by high single digits in 2016.
The analyst stated "though we are disappointed in the enterprise segment in DCG, we note all other segments of this business are growing at or above expectations and will soon account for the majority of DCG revenue".
No change to the Buy rating.
Shares of Intel closed at $37.75 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Skyworks Solutions (SWKS) PT Raised to $105 at Oppenheimer Following 1Q Report
- M&T Bank (MTB) PT Raised to $165 at FBR Capital Following 4Q Beat
- Union Pacific (UNP) PT Raised to $102 at Stifel Following 4Q Report
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change, Earnings
Related EntitiesNeedham & Company
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!